Metabolite profiling of obese individuals before and after a one year weight loss program

Geidenstam, Nina; Al-Majdoub, Mahmoud; Ekman, Mari; Sartipy, Peter; Ridderstråle, Martin

doi:10.1038/ijo.2017.124

Cited by 36 publications

(51 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The second block includes five studies focused on studying the differential responses of obese and non-obese subjects to dietary challenges (Table 2 ) (Badoud et al 2015b ; Baker et al 2015 ; Geidenstam et al 2014 ; Bak et al 2018 ). The third block comprises three studies that used metabolomics to predict weight loss (Geidenstam et al 2017a , b ; Stroeve et al 2016 ) and 11 randomized clinical trials (RCTs) aimed to assess the effects of weight loss interventions (both hypocaloric diet programs and exercise interventions) on the metabolomic profiles of overweight or obese human subjects (Table 2 ) (Almanza-Aguilera et al 2018 ; Duft et al 2017 ; Kang et al 2018 ; Leal-Witt et al 2018 ; Meucci et al 2017 ; Mills et al 2019 ; Munukka et al 2018 ; Palau-Rodriguez et al 2019 ; Perez-Cornago et al 2014 ; Zheng et al 2016a , b ). Additionally, the fourth block includes 11 articles that studied the effects of specific dietary patterns or dietary compounds on obesity-related metabolic alterations in humans, such as inflammation or oxidative stress (Table 3 ) (Baldrick et al 2018 ; Gu et al 2013 ; Hernández-Alonso et al 2019 ; Hibberd et al 2019 ; Kim et al 2013 ; Kim et al 2017 ; Mayengbam et al 2019 ; Nieman et al 2012a , b ; Romo-Hualde et al 2018 ; Xu et al 2018 ).…”

Section: Resultsmentioning

confidence: 99%

“…Geidenstam et al ( 2017a ) identified changes in the plasma levels of several AAs after weight loss for nine months and weight maintenance in obese subjects and evaluated in a replication cohort (Table 2 ). Of the 21 detected AAs, only tyrosine approached the lean reference profile (no initial increase) after weight loss, and this profile was maintained after weight maintenance (Geidenstam et al 2017a ).…”

Section: Resultsmentioning

confidence: 99%

“…Subjects enrolled in a 1-year weight loss program were classified into two groups according to the achievement (< or > 10% weight loss) (Geidenstam et al 2017a ). The analysis revealed that decreased levels of 1-methyladenosine, alanine, proline, trans-cinnamic acid, tyrosine, and the BCAAs were associated with a ≥ 10% weight loss.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

2019

View full text Add to dashboard Cite

Introduction Obesity is a disorder characterized by a disproportionate increase in body weight in relation to height, mainly due to the accumulation of fat, and is considered a pandemic of the present century by many international health institutions. It is associated with several non-communicable chronic diseases, namely, metabolic syndrome, type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and cancer. Metabolomics is a useful tool to evaluate changes in metabolites due to being overweight and obesity at the body fluid and cellular levels and to ascertain metabolic changes in metabolically unhealthy overweight and obese individuals (MUHO) compared to metabolically healthy individuals (MHO). Objectives We aimed to conduct a systematic review (SR) of human studies focused on identifying metabolomic signatures in obese individuals and obesity-related metabolic alterations, such as inflammation or oxidative stress. Methods We reviewed the literature to identify studies investigating the metabolomics profile of human obesity and that were published up to May 7th, 2019 in SCOPUS and PubMed through an SR. The quality of reporting was evaluated using an adapted of QUADOMICS. Results Thirty-three articles were included and classified according to four types of approaches. (i) studying the metabolic signature of obesity, (ii) studying the differential responses of obese and non-obese subjects to dietary challenges (iii) studies that used metabolomics to predict weight loss and aimed to assess the effects of weight loss interventions on the metabolomics profiles of overweight or obese human subjects (iv) articles that studied the effects of specific dietary patterns or dietary compounds on obesity-related metabolic alterations in humans. Conclusion The present SR provides state-of-the-art information about the use of metabolomics as an approach to understanding the dynamics of metabolic processes involved in human obesity and emphasizes metabolic signatures related to obesity phenotypes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

2019

View full text Add to dashboard Cite

show abstract

“…Recently, Geidenstam et al reported that baseline levels of serum xylitol showed an inverse association with a ≥10% weight loss in obese subjects fed low-calorie diet [ 37 ]. Firmicutes phylum accelerates degradation of food component to supply energy to host, it is, therefore, known as obesity-related bacterial phylum [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice

et al. 2017

View full text Add to dashboard Cite

The sugar alcohol xylitol inhibits the growth of some bacterial species including Streptococcus mutans. It is used as a food additive to prevent caries. We previously showed that 1.5–4.0 g/kg body weight/day xylitol as part of a high-fat diet (HFD) improved lipid metabolism in rats. However, the effects of lower daily doses of dietary xylitol on gut microbiota and lipid metabolism are unclear. We examined the effect of 40 and 200 mg/kg body weight/day xylitol intake on gut microbiota and lipid metabolism in mice. Bacterial compositions were characterized by denaturing gradient gel electrophoresis and targeted real-time PCR. Luminal metabolites were determined by capillary electrophoresis electrospray ionization time-of-flight mass spectrometry. Plasma lipid parameters and glucose tolerance were examined. Dietary supplementation with low- or medium-dose xylitol (40 or 194 mg/kg body weight/day, respectively) significantly altered the fecal microbiota composition in mice. Relative to mice not fed xylitol, the addition of medium-dose xylitol to a regular and HFD in experimental mice reduced the abundance of fecal Bacteroidetes phylum and the genus Barnesiella, whereas the abundance of Firmicutes phylum and the genus Prevotella was increased in mice fed an HFD with medium-dose dietary xylitol. Body composition, hepatic and serum lipid parameters, oral glucose tolerance, and luminal metabolites were unaffected by xylitol consumption. In mice, 40 and 194 mg/kg body weight/day xylitol in the diet induced gradual changes in gut microbiota but not in lipid metabolism.

show abstract

“…The clinical practice of modern Chinese medicine has found that WLS has the effect on reducing weight and fat. Additionally, recent studies have found significant changes in plasma metabolite profiles in obese patients, including increased levels of all branched‐chain amino acids (BCAAs; valine, leucine, and isoleucine) and downstream BCAA metabolites , such as branched‐chain keto acids and short‐chain acylcarnitines as well as glycerol and glycerophosphocholines , which are related to fluid imbalance. However, the effect of WLS on the regulation of body fluid‐plasma metabolism has not been defined.…”

Section: Introductionmentioning

confidence: 99%

Wulingsan (Oryeongsan/Goreisan) ameliorate lipid metabolism of obesity rats via regulation of the plasma metabolic profiling

Xue

Xue²,

Cui

et al. 2019

Biotech and App Biochem

View full text Add to dashboard Cite

Objectives: Wulingsan has been used to cure disease about disorders related to fluid balance for thousands of years. The clinical practice of modern Chinese medicine has found that Wulingsan has the effect on reducing weight and fat, but its mechanism is not clear. This study investigated its effects on obesity rats and explored the underlying mechanisms by analyzing the plasma metabolic profiling. Methods: The effects of Wulingsan on obesity were evaluated with obesity rats induced by high-fat diet. Ultra high performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (UPLC-Q-TOF/MS) was performed to discover potential biomarkers and evaluate whether Wulingsan could regulate these biomarkers. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) in serum were assessed by ELISA kits. Results: Remarkably, TG, TC, HDL-C and LDL-C in obesity rats were ameliorated after oral administration of Wulingsan. Further investigation indicated that the plasma metabolic profiles were clearly improved. Twelve potential biomarkers were identified. After intervention, these biomarkers turned back to normal level at some extent. Conclusion: The results showed that Wulingsan extract groups were normalized. Additionally, this study also showed that the metabonomics method was a promising tool to unravel how traditional Chinese medicines worked and these data can provide scientific basis for clinical application of Wulingsan.

show abstract

Metabolite profiling of obese individuals before and after a one year weight loss program

Cited by 36 publications

References 41 publications

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies

Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice

Wulingsan (Oryeongsan/Goreisan) ameliorate lipid metabolism of obesity rats via regulation of the plasma metabolic profiling

Contact Info

Product

Resources

About